The crude and adjusted ORs for the MUTYH His/His genotype compared with Gln/Gln genotype showed a increased risk for lung cancer (crude odds ratio [OR] 3.25, 95% confidence interval [95%CI] 1.44–7.36, p = 0.005; adjusted OR 3.03, 95%CI 1.31–7.00, p = 0.010, respectively), whereas there was no significant increase for the Gln/His genotype (crude OR 1.39, 95%CI 0.74–2.62, p = 0.309; adjusted OR 1.35,

95%CI 0.70–2.61, p = 0.376, respectively). Table 2 Genotype distribution in lung cancer and Allele frequency                       Allele frequency Genotype   patients (n = 108) controls (n = 121) crude   adjusted     patients controls     n % n % OR (95%CI) P-value OR (95%CI)a P-value   % % OGG1                           Ser/Ser 27 25.0 39 32.2 1.00   1.00   Ser 0.505 0.546   Ser/Cys 55 50.9 54 44.6 1.47 (0.79–2.73) 0.221 1.52 (0.80–2.91) selleck chemical 0.204 Cys 0.495 0.455   Cys/Cys 26 24.1 28 23.1 1.34 (0.65–2.77) 0.427 1.47 (0.69–3.12) 0.313       MUTYH                         https://www.selleckchem.com/products/Rapamycin.html   Gln/Gln 22 20.3 37 30.6 1.00   1.00   Gln 0.468 0.591   Gln/His 57 52.8 69 57.0 1.39 (0.74–2.62) 0.309 1.35 (0.70–2.61) 0.376 His 0.532 0.409   His/His 29 26.9 15 12.4 3.25 (1.44–7.36) 0.005 3.03 (1.31–7.00) 0.010       a: OR adjusted for gender, age, smoking

habit Table 3 summarizes the genotype distribution for lung adenocarcinoma and squamous cell carcinoma, showing the OR adjusted for gender, age, and smoking habits. The crude and adjusted ORs for the OGG1 Ser/Cys or Cys/Cys genotypes compared with the Ser/Ser genotype were not significant for adenocarcinoma and squamous cell carcinoma. The crude ORs for the MUTYH His/His genotype compared with Gln/Gln genotype showed a significant increase for both adenocarcinoma and squamous cell carcinoma (OR 3.04, 95%CI 1.18–7.82, p = 0.021 for adenocarcinoma; OR 4.11, 95%CI 1.27–13.33, p = 0.019, respectively). The adjusted ORs for the PTK6 MUTYH His/His genotype compared with Gln/Gln genotype showed a borderline significant

for adenocarcinoma and squamous cell carcinoma (OR 2.50, 95%CI 0.95–6.62, p = 0.065 for adenocarcinoma; OR 3.20, 95%CI 0.89–11.49, p = 0.075 for squamous cell carcinoma, respectively). While, there was no significant increase for the MUTYH Gln/His genotype in the histological types. Table 3 Genotype distribution in relation to histological type in lung cancer Genotype Adenocarcinoma Squamous Cell Carcinoma   patients (n = 67) controls (n = 121) crude adjusted patients (n = 31) controls (n = 121) crude adjusted   n % n % OR (95%CI)a P-value OR (95%CI)a P-value n % n % OR (95%CI)a P-value OR (95%CI)a P-value OGG1                                 Ser/Ser 17 25.4 39 32.2 1.00   1.00   8 25.8 39 32.3 1.00   1.00   Ser/Cys 33 49.2 54 44.6 1.40 (0.69–2.87) 0.355 1.34 (0.64–2.81) 0.439 16 51.6 54 44.6 1.44 (0.56–3.71) 0.445 1.23 (0.44–3.43) 0.695 Cys/Cys 17 25.4 28 23.1 1.39 (0.61–3.19) 0.434 1.31 (0.56–3.08) 0.530 7 22.6 28 23.1 1.22 (0.40–3.75) 0.730 1.54 (0.45–5.